University of Oulu

Ali Salehi, Parvaneh Naserzadeh, Parastoo Tarighi, Elham Afjeh-Dana, Masoud Akhshik, Amir Jafari, Pooyan Mackvandi, Behnaz Ashtari, Masoud Mozafari, Fabrication of a microfluidic device for probiotic drug's dosage screening: Precision Medicine for Breast Cancer Treatment, Translational Oncology, Volume 34, 2023, 101674, ISSN 1936-5233,

Fabrication of a microfluidic device for probiotic drug’s dosage screening : precision medicine for breast cancer treatment

Saved in:
Author: Salehi, Ali1,2; Naserzadeh, Parvaneh3; Tarighi, Parastoo4;
Organizations: 1Radiation Biology Research Centre, Iran University of Medical Sciences, Tehran, Iran
2Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences. Tehran, Iran
3Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
4Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences. Tehran, Iran
5Centre for Biocomposites and Biomaterials Processing. University of Toronto, Canada
6EPICentre, University of Windsor, Canada
7Centre for Materials Interfaces, Istituto Italiano di Tecnologia, viale Rinaldo Piaggio 34, Pontedera, 56025 Pisa, Italy
8Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
9Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 12 MB)
Persistent link:
Language: English
Published: Elsevier, 2023
Publish Date: 2023-09-18


Breast cancer is the most common cancer in women; it has been affecting the lives of millions each year globally and microfluidic devices seem to be a promising method for the future advancements in this field. This research uses a dynamic cell culture condition in a microfluidic concentration gradient device, helping us to assess breast anticancer activities of probiotic strains against MCF-7 cells. It has been shown that MCF-7 cells could grow and proliferate for at least 24 h; however, a specific concentration of probiotic supernatant could induce more cell death signaling population after 48 h. One of our key findings was that our evaluated optimum dose (7.8 mg/L) was less than the conventional static cell culture treatment dose (12 mg/L). To determine the most effective dose over time and the percentage of apoptosis versus necrosis, flowcytometric assessment was performed. Exposing the MCF-7 cells to probiotic supernatant after 6, 24 and 48 h, confirmed that the apoptotic and necrotic cell death signaling were concentration and time dependent. We have shown a case that these types of microfluidics platforms performing dynamic cell culture could be beneficial in personalized medicine and cancer therapy.

see all

Series: Translational oncology
ISSN: 1936-5233
ISSN-E: 1936-5233
ISSN-L: 1936-5233
Volume: 34
Article number: 101674
DOI: 10.1016/j.tranon.2023.101674
Type of Publication: A1 Journal article – refereed
Field of Science: 318 Medical biotechnology
3122 Cancers
Funding: This research was supported by the Faculty of Advanced Technologies in medicine, at the Iran University of Medical Sciences.
Copyright information: © 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (